CA2204144A1 - Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase - Google Patents

Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase

Info

Publication number
CA2204144A1
CA2204144A1 CA002204144A CA2204144A CA2204144A1 CA 2204144 A1 CA2204144 A1 CA 2204144A1 CA 002204144 A CA002204144 A CA 002204144A CA 2204144 A CA2204144 A CA 2204144A CA 2204144 A1 CA2204144 A1 CA 2204144A1
Authority
CA
Canada
Prior art keywords
obn
trp
tyr
ala
cbz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002204144A
Other languages
English (en)
Inventor
Francis J. Tinney
Judith Sebolt-Leopold
Gary Louis Bolton
Daniele Leonard
Donald Hupe
Tomi Sawyer
Alfred Campbell
Richard Gowan
John Cooke Hodges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2204144A1 publication Critical patent/CA2204144A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Cette invention se rapporte à des inhibiteurs de l'enzyme protéine:farnésyle transférase, ainsi qu'à des procédés pour leur préparation et des compositions pharmaceutiques les contenant, qui sont utiles pour lutter contre les maladies prolifératives des tissus, telles que le cancer et la resténose.
CA002204144A 1994-12-09 1995-10-27 Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase Abandoned CA2204144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35347394A 1994-12-09 1994-12-09
US353,473 1994-12-09

Publications (1)

Publication Number Publication Date
CA2204144A1 true CA2204144A1 (fr) 1996-06-13

Family

ID=23389273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002204144A Abandoned CA2204144A1 (fr) 1994-12-09 1995-10-27 Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase

Country Status (4)

Country Link
JP (1) JPH10510261A (fr)
AU (1) AU3971295A (fr)
CA (1) CA2204144A1 (fr)
WO (1) WO1996017861A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
SI2010528T1 (en) 2006-04-19 2018-02-28 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
CA2685967A1 (fr) 2007-05-21 2008-11-21 Novartis Ag Inhibiteurs de cfs-1r, compositions et methodes d'utilisation connexes
CA2690191C (fr) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
CA2807307C (fr) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (fr) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (fr) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3569598A1 (fr) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
EP2844261B1 (fr) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Compositions de petit acide nucléique interférent (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (fr) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
US9266824B2 (en) 2014-01-13 2016-02-23 Warsaw Orthopedic, Inc. Methods and compositions for making an amino acid triisocyanate
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dependantes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528486A2 (fr) * 1991-08-16 1993-02-24 Merck & Co. Inc. Inhibiteur de farnésyl-protéine transférase n'étant pas un substrat
JPH09504295A (ja) * 1993-10-25 1997-04-28 パーク・デイビス・アンド・カンパニー タンパク質：ファルネシルトランスフェラーゼの置換されたテトラ‐およびペンタペプチド阻害剤

Also Published As

Publication number Publication date
MX9703208A (es) 1997-07-31
WO1996017861A1 (fr) 1996-06-13
AU3971295A (en) 1996-06-26
JPH10510261A (ja) 1998-10-06

Similar Documents

Publication Publication Date Title
AU682906B2 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
CA2204144A1 (fr) Tetrapeptide et pentapeptide substitues servant d'inhibiteurs de la proteine:farnesyle transferase
AU681454B2 (en) Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase
AU699629B2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
TW409129B (en) Factor Xa inhibitors
WO2001002424A2 (fr) Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
US5830868A (en) Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase
US5763577A (en) Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
PT92496A (pt) Processo para a preparacao de derivados de dipeptideos com accao inibitoria de enzimas, e de composicoes farmaceuticas que os contem
MXPA97003208A (en) Tetra-y pentapeptidos substituidos deproteina inhibitors, farnesil transfer
JP3009718B2 (ja) 新規ペプチド、その製造法及び用途
JP3009719B2 (ja) 新規ペプチド、その製造法及び用途
JP3012291B2 (ja) 新規ペプチド、その製造方法及び用途
JP2965682B2 (ja) 新規ペプチド、その製造法及び用途
JP3009720B2 (ja) 新規ペプチド、その製造法及び用途
JP2965683B2 (ja) 新規ペプチド、それを製造する方法及び用途
JPH07316193A (ja) ペプチド誘導体およびその用途
JP3086235B2 (ja) 新規ペプチド及び用途
JP3012292B2 (ja) 新規ペプチド、その製造法及び用途
JP3031692B2 (ja) 新規ペプチド、それを製造する方法及び用途
JPH04264097A (ja) ペプチド誘導体およびその用途
JPH0812594A (ja) アンジオテンシンｉ変換酵素阻害ペプチド誘導体

Legal Events

Date Code Title Description
FZDE Dead